Delivery Time: ~7 days
What is Evista?
Evista is an oral SERM that exerts its estrogenic action on bones and anti-estrogenic action on breast and uterus. It comes as tablets with 60 mg of Raloxifene hydrochloride as key ingredient. It works by increasing mineral density of bones and binding to estrogen receptors in the breast. Due to its ability to decrease estrogen effects, the drug helps to reduce the risk of breast cancer development. The drug is licensed only for administration in postmenopausal women.
When is Evista prescribed?
Evista is prescribed to postmenopausal women to prevent and treat osteoporosis and to reduce the risk of invasive breast cancer. It is also prescribed to postmenopausal women without osteoporosis, but at high risk for invasive breast cancer. The drug is also used to reduce breast density. Supplemental calcium and vitamin D intake is required when used for treating or preventing osteoporosis.
How to take Evista?
Evista dosage is the same for all patients, regardless of their age, weight and the condition treated. It is administered in the dose of 60 mg (one tablet) once daily. The medication can be taken regardless to meals, but preferably at one and the same time every day. The optimum duration of treatment is determined by the attending physician and usually comprises from 3 to 5 years. He may also advise you on receiving supplemental calcium and vitamin D while on the drug.
What are Evista side effects?
Evista may spur hot flashes, sweating, joint pain, flu-like symptoms and water retention. These side effects are generally mild and can be easily managed. However, if these symptoms persist or worsen seek medical attention. Notify your attending physician promptly if you develop swelling, sudden rash or unexplained uterine bleeding. In rare cases some individuals are at increased risk for developing blood clots, including stroke, pulmonary embolism and deep vein thrombosis during the first 4 months of the drug usage.
When is Evista contraindicated?
Evista is contraindicated to women with a history of pulmonary embolism, deep vein thrombosis and retinal vein thrombosis. It is also contraindicated to pregnant and nursing women. The drug is not intended for cardiovascular disease prevention. Caution should be exercised when administering the drug to women with renal or hepatic impairment.